Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Nov 01, 2024

BUY
$3.66 - $5.34 $138,714 - $202,386
37,900 New
37,900 $152,000
Q2 2024

Aug 09, 2024

BUY
$3.66 - $5.34 $15,738 - $22,962
4,300 Added 12.8%
37,900 $152,000
Q1 2024

May 09, 2024

BUY
$4.19 - $5.59 $140,784 - $187,824
33,600 New
33,600 $167,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $383M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Belvedere Trading LLC Portfolio

Follow Belvedere Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belvedere Trading LLC with notifications on news.